Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1165-1171

  Sasaki, Takamitsu ^a   Kuniyasu, Hiroki ^b   Luo, Yi ^b   Kato, Daisuke ^a   Shinya, Satoshi ^a   Fujii, Kiyomu ^b   Ohmori, Hitoshi ^b   Yamashita, Yuichi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN; WNT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MEMBRANE; CELL SHAPE; CELL STRUCTURE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GALLBLADDER CANCER; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

APOPTOSIS; BETA CATENIN; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GALLBLADDER NEOPLASMS; GLYCOGEN SYNTHASE KINASE 3; GTP-BINDING PROTEINS; HEPATOCYTE GROWTH FACTOR; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; WNT SIGNALING PATHWAY;

EID: 84861660952     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02264.x     Document Type: Article

References (40)

1. Center for Cancer Control and Information Services, ed. Current Cancer Statistics in Japan. Tokyo, Japan: National Cancer Center, 2011. Available from URL:
2. Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 1996; 224: 639-46.
3. Dawes LG. Gallbladder cancer. Cancer Treat Res 2001; 109: 145-55.
4. Bartlett DL. Gallbladder cancer. Semin Surg Oncol 2000; 19: 145-55.
5. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
6. Harder J, Waiz O, Otto F et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15: 4511-7.
7. Kaufman M, Mehrotra B, Limaye S et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci 2008; 5: 285-91.
8. Leone F, Cavalloni G, Pignochino Y et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006; 12: 1680-5.
9. Ooi A, Suzuki S, Nakazawa K et al. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. Anticancer Res 2009; 29: 19-26.
10. Pignochino Y, Sarotto I, Peraldo-Neia C et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10: 631.
11. Sanada Y, Osada S, Tokuyama Y et al. Critical role of c-Met and Ki67 in progress of biliary carcinoma. Am Surg 2010; 76: 372-9.
12. Moon WS, Park HS, Lee H et al. Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat 2005; 37: 171-6.
13. Matsumoto K, Date K, Shimura H, Nakamura T. Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. Jpn J Cancer Res 1996; 87: 702-10.
14. Kitamura K, Kasuya K, Tsuchida A et al. Immunohistochemical analysis of transforming growth factor beta in gallbladder cancer. Oncol Rep 2003; 10: 327-32.
15. Yukawa M, Fujimori T, Hirayama D et al. Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. Hum Pathol 1993; 24: 37-40.
16. Chang HY, Kao MC, Way TD, Ho CT, Fu E. Diosgenin suppresses HGF-induced epithelial-mesenchymal transition by down-regulation of MDM2 and vimentin. J Agric Food Chem 2011; 59: 5357-63.
17. Barr S, Thomson S, Buck E et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008; 25: 685-93.
18. McConkey DJ, Choi W, Marquis L et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009; 28: 335-44.
19. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 314-23.
20. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007; 98: 1512-20.
21. Lee MY, Chou CY, Tang MJ, Shen MR. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res 2008; 14: 4743-50.
22. Fujii K, Luo Y, Sasahira T, Denda A, Ohmori H, Kuniyasu H. Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells. Cell Prolif 2009; 42: 701-9.
23. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622-34.
24. Kimura Y, Furuhata T, Mukaiya M et al. Frequent beta-catenin alteration in gallbladder carcinomas. J Exp Clin Cancer Res 2003; 22: 321-8.
25. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 2007; 3: 18-29.
26. Raimondi C, Gianni W, Cortesi E, Gazzaniga P. Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug Targets 2010; 10: 496-508.
27. Sarkar FH, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 2009; 64: 489-500.
28. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
29. Hirata K, Ajiki T, Okazaki T, Horiuchi H, Fujita T, Kuroda Y. Frequent occurrence of abnormal E-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis. Oncology 2006; 71: 102-10.
30. Priya TP, Kapoor VK, Krishnani N, Agrawal V, Agrawal S. Role of E-cadherin gene in gall bladder cancer and its precursor lesions. Virchows Arch 2010; 456: 507-14.
31. Koga Y, Kitajima Y, Miyoshi A et al. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol 2005; 12: 354-63.
32. Zavadil J, Narasimhan M, Blumenberg M, Schneider RJ. Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 2007; 185: 157-61.
33. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010; 10: 219-22.
34. Shen Y, Hirsch DS, Sasiela CA, Wu WJ. Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway. J Biol Chem 2008; 283: 5127-37.
35. Georgopoulos NT, Kirkwood LA, Walker DC, Southgate J. Differential regulation of growth-promoting signalling pathways by E-cadherin. PLoS ONE 2010; 5: e13621.
36. Kim S, Schein AJ, Nadel JA. E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 289: L1049-60.
37. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004; 23: 1739-48.
38. Takahashi K, Suzuki K. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res 1996; 226: 214-22.
39. Xu L, Hausmann M, Dietmaier W et al. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer 2010; 10: 302.
40. Ariyama H, Qin B, Baba E et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 2006; 97: 724-34.